Juan Pinelli

927 total citations · 1 hit paper
8 papers, 655 citations indexed

About

Juan Pinelli is a scholar working on Surgery, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Juan Pinelli has authored 8 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Surgery, 2 papers in Molecular Biology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Juan Pinelli's work include Urinary and Genital Oncology Studies (3 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Juan Pinelli is often cited by papers focused on Urinary and Genital Oncology Studies (3 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Juan Pinelli collaborates with scholars based in United States, France and Canada. Juan Pinelli's co-authors include Noah M. Hahn, Elisabeth I. Heath, Jonathan E. Rosenberg, Peter H. O’Donnell, Bradley A. McGregor, Evan Y. Yu, Arjun Vasant Balar, Daniel P. Petrylak, Elaina M. Gartner and Amal Melhem‐Bertrandt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Juan Pinelli

7 papers receiving 651 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2019 435 citations Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juan Pinelli United States	5	331	322	161	107	86	8	655
Ying‐Ju Kuo Taiwan	15	361 1.1×	372 1.2×	67 0.4×	134 1.3×	69 0.8×	39	714
Jean Lopategui United States	13	209 0.6×	115 0.4×	156 1.0×	129 1.2×	121 1.4×	27	521
Mario L. Marques‐Piubelli United States	14	269 0.8×	98 0.3×	156 1.0×	85 0.8×	67 0.8×	47	480
Amir Afrogheh South Africa	11	200 0.6×	385 1.2×	109 0.7×	142 1.3×	42 0.5×	33	726
Paola Ghione United States	14	254 0.8×	144 0.4×	326 2.0×	88 0.8×	28 0.3×	64	594
Loreto Spencer Chile	13	239 0.7×	117 0.4×	73 0.5×	191 1.8×	138 1.6×	34	604
Kathrin Glatz Switzerland	8	336 1.0×	128 0.4×	55 0.3×	97 0.9×	118 1.4×	12	581
A. B. Lopez Denmark	7	250 0.8×	187 0.6×	147 0.9×	50 0.5×	31 0.4×	9	517
Dan Ferariu Romania	8	288 0.9×	145 0.5×	64 0.4×	51 0.5×	88 1.0×	51	499
Seung-Myoung Son South Korea	11	172 0.5×	88 0.3×	99 0.6×	108 1.0×	252 2.9×	53	488

Countries citing papers authored by Juan Pinelli

Since Specialization

Citations

This map shows the geographic impact of Juan Pinelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan Pinelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan Pinelli more than expected).

Fields of papers citing papers by Juan Pinelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan Pinelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan Pinelli. The network helps show where Juan Pinelli may publish in the future.

Co-authorship network of co-authors of Juan Pinelli

This figure shows the co-authorship network connecting the top 25 collaborators of Juan Pinelli. A scholar is included among the top collaborators of Juan Pinelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan Pinelli. Juan Pinelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Grieselhuber, Nicole R., Anjali S. Advani, Abdulraheem Yacoub, et al.. (2024). PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study. Blood. 144(Supplement 1). 1840–1840.

2.

Henry, Jason T., Janice M. Mehnert, Erika Rudnicki, Juan Pinelli, & Adil Daud. (2023). Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).. Journal of Clinical Oncology. 41(16_suppl). TPS9597–TPS9597. 1 indexed citations

3.

Rosenberg, Jonathan E., Peter H. O’Donnell, Arjun Vasant Balar, et al.. (2019). Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology. 37(29). 2592–2600. 435 indexed citations breakdown →

4.

McGregor, Bradley A., Peter H. O’Donnell, Arjun Vasant Balar, et al.. (2019). Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1. Annals of Oncology. 30. v367–v368. 3 indexed citations

5.

Petrylak, Daniel P., Arjun Vasant Balar, Peter H. O’Donnell, et al.. (2019). EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.. Journal of Clinical Oncology. 37(18_suppl). 4505–4505. 37 indexed citations

6.

Pro, Barbara, Ranjana H. Advani, Pauline Brice, et al.. (2017). Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 130(25). 2709–2717. 161 indexed citations

7.

Jenkins, Isaac, Lynne P. Taylor, Raymond Farah, et al.. (2016). Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation. 51(7). 973–979. 5 indexed citations

8.

Pro, Barbara, Ranjana H. Advani, Pauline Brice, et al.. (2016). Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood. 128(22). 4144–4144. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact